{"id":60127,"date":"2024-10-02T12:04:58","date_gmt":"2024-10-02T12:04:58","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/10\/02\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/"},"modified":"2024-10-02T12:04:58","modified_gmt":"2024-10-02T12:04:58","slug":"rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/","title":{"rendered":"Rudolph E. Tanzi, Co-Director of MassGeneral Institute for Neurodegenerative Disease, Chairs Cognos Neurodegenerative Scientific and Clinical Advisory Board"},"content":{"rendered":"<div>\n<p>INGLEWOOD, California, Oct.  02, 2024  (GLOBE NEWSWIRE) &#8212; Cognos Therapeutics, a private hi-tech medical technology company focused on the development of advanced AI implantable pump SINNAIS for smart delivery of neurological and oncological treatments, is pleased to announce the appointment of Dr. Rudolph E. Tanzi as Chairman of its Neurodegenerative Scientific and Clinical Advisory Board (SAB). Dr. Tanzi, a prominent investigator and Professor of Neurology at Harvard University and Massachusetts General Hospital, brings over four decades of expertise in Alzheimer\u2019s research.<\/p>\n<p>Cognos is pioneering the SINNAIS technology, which delivers drugs locally with metronomic dosing and real-time biofeedback capabilities, all supported by cloud connectivity and AI. The company is also developing a second-generation version of SINNAIS aimed at Alzheimer\u2019s treatment, utilizing micro-dialysis of cerebrospinal fluid (CSF) technology to target beta-amyloid concentrations.<\/p>\n<p>The company has successfully completed the proof of concept for SINNAIS, demonstrating that SINNAIS it meets design specifications in live large survival animal models. SINNAIS delivers drugs locally and metronomically through cloud connectivity. Additionally, the company has held a series of meetings with the FDA to prepare for the PMA filing process using an expedited path that shortens approval to two years and requires no human clinical trials, only GLP animal studies. The initial disease models for human clinical trials will focus on leptomeningeal carcinomatosis (LC), glioblastoma multiforme (GBM), and pancreatic cancer.<\/p>\n<p>Dr. Tanzi\u2019s illustrious career includes serving as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School, Director of the Genetics and Aging Research Unit, Director of the McCance Center for Brain Health, and Co-Director of the Mass General Institute for Neurodegenerative Disease at Massachusetts General Hospital. His groundbreaking research has led to the identification of key genes linked to Alzheimer\u2019s, such as APP, PSEN1, PSEN2, ADAM10 and CD33, providing critical insights into the genetic components of the disease. Dr. Rudy Tanzi has dedicated over four decades of research and clinical work to understanding of Alzheimer\u2019s disease, making him one of the most influential scientists in the field of neurodegenerative diseases in the 20th and 21st centuries and our time.<\/p>\n<p>Having accepted Cognos&#8217;s invitation to lead the SAB, Dr. Tanzi aims to apply his extensive findings to help enhance the effectiveness of the SINNAIS technology in clinical trials. His research has hugely shaped the amyloid cascade hypothesis, emphasizing the role of beta-amyloid deposition in Alzheimer\u2019s pathology and the importance of microglia in maintaining brain health. Furthermore, Dr. Tanzi and team\u2019s development of Alzheimer\u2019s in a Dish&#x2122;, a mini human brain organoid that recreates decades of Alzheimer\u2019s neuropathology in just 6 weeks, has revolutionized drug discovery. <\/p>\n<p>Dr. Tanzi will advise Cognos how to leverage these findings in therapies using the Cognos SINNAIS to measure beta-amyloid concentrations, siphon CSF, and filter out amyloid and other protein debris. The objective is to establish a viable treatment pathway that could lead to the first mainstream therapy for Alzheimer\u2019s disease, aiming to maintain and potentially reduce beta-amyloid levels in patients to prevent progression of disease.<\/p>\n<p>\u201cWe are thrilled to welcome Dr. Tanzi to our team,\u201d said Frank Adell, Chief Executive Officer at Cognos Therapeutics. \u201cHis unparalleled expertise and innovative research will be invaluable as we work towards transforming the landscape of Alzheimer\u2019s treatment.\u201d<\/p>\n<p>Dr. Tanzi\u2019s acceptance of this role reflects a shared vision between Cognos and his ongoing commitment to advancing the understanding and treatment of neurodegenerative diseases. Together, we aspire to bring meaningful solutions to the millions affected by Alzheimer\u2019s.<\/p>\n<p>Additional members of SAB who will work closely with Dr. Tanzi are Dr. Roger Kornberg who is a Co-Founder of Cognos, biochemist and professor of structural biology at Stanford and a 2006 Nobel laureate will Co-Chair our SAB with Dr. Tanzi. And Dr. Thomas Chen who is a CO-Founder and Chairman of Cognos Neurology and Oncology Advisory board.<\/p>\n<p>The company is at per IPO stage and currently raising capital through private mezzanine round.<\/p>\n<p><strong>Investors:<\/strong><br \/><strong>Gilmartin Group<\/strong><br \/>Vivian Cervantes<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4cbBha3F0LKmEVCM2igcu_x3z4oIYks3vURsRwW-tiCy1amS3Mz19K8Mm6uVNZeXPpzIIE8DNVLW9nmUXEIXeg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"IR@cognosthx.com\">IR@cognosthx.com<\/a><\/p>\n<p><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDc2NzlkMGItYjkzNC00OGYzLWJkOWItZTMzM2M0OGIxNzZmLTUwMDEyNjk2Mw==\/tiny\/Cognos-Therapeutics-Inc.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>INGLEWOOD, California, Oct. 02, 2024 (GLOBE NEWSWIRE) &#8212; Cognos Therapeutics, a private hi-tech medical technology company focused on the development of advanced AI implantable pump SINNAIS for smart delivery of neurological and oncological treatments, is pleased to announce the appointment of Dr. Rudolph E. Tanzi as Chairman of its Neurodegenerative Scientific and Clinical Advisory Board [&#8230;]\n","protected":false},"author":1,"featured_media":60128,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-60127","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Rudolph E. Tanzi, Co-Director of MassGeneral Institute for Neurodegenerative Disease, Chairs Cognos Neurodegenerative Scientific and Clinical Advisory Board - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rudolph E. Tanzi, Co-Director of MassGeneral Institute for Neurodegenerative Disease, Chairs Cognos Neurodegenerative Scientific and Clinical Advisory Board\" \/>\n<meta property=\"og:description\" content=\"INGLEWOOD, California, Oct. 02, 2024 (GLOBE NEWSWIRE) &#8212; Cognos Therapeutics, a private hi-tech medical technology company focused on the develop\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-02T12:04:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/Cognos-Therapeutics-Inc.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Rudolph E. Tanzi, Co-Director of MassGeneral Institute for Neurodegenerative Disease, Chairs Cognos Neurodegenerative Scientific and Clinical Advisory Board\",\"datePublished\":\"2024-10-02T12:04:58+00:00\",\"dateModified\":\"2024-10-02T12:04:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/\"},\"wordCount\":682,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/\",\"name\":\"Rudolph E. Tanzi, Co-Director of MassGeneral Institute for Neurodegenerative Disease, Chairs Cognos Neurodegenerative Scientific and Clinical Advisory Board - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-10-02T12:04:58+00:00\",\"dateModified\":\"2024-10-02T12:04:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rudolph E. Tanzi, Co-Director of MassGeneral Institute for Neurodegenerative Disease, Chairs Cognos Neurodegenerative Scientific and Clinical Advisory Board\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rudolph E. Tanzi, Co-Director of MassGeneral Institute for Neurodegenerative Disease, Chairs Cognos Neurodegenerative Scientific and Clinical Advisory Board - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/","og_locale":"en_US","og_type":"article","og_title":"Rudolph E. Tanzi, Co-Director of MassGeneral Institute for Neurodegenerative Disease, Chairs Cognos Neurodegenerative Scientific and Clinical Advisory Board","og_description":"INGLEWOOD, California, Oct. 02, 2024 (GLOBE NEWSWIRE) &#8212; Cognos Therapeutics, a private hi-tech medical technology company focused on the develop","og_url":"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-10-02T12:04:58+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/Cognos-Therapeutics-Inc.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Rudolph E. Tanzi, Co-Director of MassGeneral Institute for Neurodegenerative Disease, Chairs Cognos Neurodegenerative Scientific and Clinical Advisory Board","datePublished":"2024-10-02T12:04:58+00:00","dateModified":"2024-10-02T12:04:58+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/"},"wordCount":682,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/","url":"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/","name":"Rudolph E. Tanzi, Co-Director of MassGeneral Institute for Neurodegenerative Disease, Chairs Cognos Neurodegenerative Scientific and Clinical Advisory Board - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-10-02T12:04:58+00:00","dateModified":"2024-10-02T12:04:58+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/rudolph-e-tanzi-co-director-of-massgeneral-institute-for-neurodegenerative-disease-chairs-cognos-neurodegenerative-scientific-and-clinical-advisory-board\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Rudolph E. Tanzi, Co-Director of MassGeneral Institute for Neurodegenerative Disease, Chairs Cognos Neurodegenerative Scientific and Clinical Advisory Board"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=60127"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60127\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/60128"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=60127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=60127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=60127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}